The first clinical procedure with the Magellan robotic catheter eKit (MRC eKit, Hansen Medical) has been successfully performed. The device was used as part of a robotic transarterial chemoembolization procedure, which was completed by Ripal Gandhi at Miami Cardiac & Vascular Institute, Miami, USA.
The MRC eKit is intended to give physicians control of third-party microcatherters through the existing Magellan Robotic Catheter 6Fr system. According to a company release, this should help reduce procedure times and radiation exposure. The US Food and Drug Administration granted approval for this device in early February 2016.
“We were able to reach several targets within the liver during today’s chemoembolization procedure to successfully deliver therapy using the Magellan Robotic Catheter eKit,” says Gandhi. “We experienced added stability and control of our smaller microcatheters, which added to the level of precision during the procedure. With the MRC eKit, we were also able to confidently do a significant portion of the procedure away from the radiation source and feel that this is a significant step in reducing radiation exposure during interventional procedures.”
The Magellan robotic system is an advanced technology that drives Magellan robotic catheters and guide wires during minimally-invasive endovascular procedures. Magellan is designed to offer procedural predictability, precision, and catheter stability as physicians navigate inside blood vessels and deliver therapy. Magellan’s remote workstation allows physicians to control robotic catheters and guide wires while seated away from the radiation field, which has been shown to reduce radiation exposure for the physician by as much as 95% in complex endovascular procedures, according to a company release.
